Dartmouth Health researchers part of the developing first nasal spray vaccine for COVID-19

Generic news release image

We are pleased to join this collaborative effort to develop and assess the safety, immunogenicity, and effectiveness of an adenovirus type 4 based vaccine expressing the SARS-CoV-2 spike protein as a novel approach to the prevention of COVID-19.

Peter F. Wright, MD

In collaboration with the National Institutes of Health (NIH) and Belgium-based viral vector manufacturer Exothera, a team of researchers at Dartmouth Health’s Dartmouth Hitchcock Medical Center (DHMC) and Dartmouth’s Geisel School of Medicine are working to develop the first intranasal COVID-19 vaccine brought to market. Led by DHMC infectious disease and international health physician Peter F. Wright, MD, this nasal-spray vaccine will not require refrigeration and does not need to be administered by a medical professional, making it a critical tool in the fight against COVID-19 in developing parts of the world.

DHMC is the sole U.S. research and development site for this novel vaccine. Clinical trials are planned in the U.S. and Africa. Intranasal vaccines show great potential to slow the transmission of COVID-19 as they have been used successfully in the past against other pathogens that enter the body via mucous membranes, including measles, rubella and other respiratory viruses.

“We are pleased to join this collaborative effort to develop and assess the safety, immunogenicity, and effectiveness of an adenovirus type 4 based vaccine expressing the SARS-CoV-2 spike protein as a novel approach to the prevention of COVID-19,” said Wright, who is also a professor of pediatrics at Geisel. “Although unique in the COVID field, the vaccine has precedent in the highly successful prevention of adenovirus respiratory disease in the United States military.”

Despite the rapid development of injectable COVID-19 vaccines, a majority of low-income and lower-middle-income countries were unable to achieve proper population coverage during initial vaccine rollouts. Even now, the percentage of the population fully vaccinated is below the level necessary to prevent continued transmission. A vaccine that can be administered by anyone via nasal spray is anticipated to be highly effective in interrupting the transmission of COVID-19, as has been done successfully with oral drops given globally to prevent polio.

Clips from the video below are cleared for use by news media outlets on all digital and broadcast platforms, with credit to Dartmouth Health.

About Dartmouth Health

Dartmouth Health, New Hampshire’s only academic health system and largest private employer, serves patients across New England. Dartmouth Health provides access to more than 2,300 providers in nearly every area of medicine, delivering care at its flagship hospital, Dartmouth Hitchcock Medical Center (DHMC) in Lebanon, NH. Its network of hospitals, outpatient centers, clinics and home care facilities, spans a broad geographical area. Year after year, DHMC is named the #1 hospital in New Hampshire by U.S. News & World Report, and is consistently recognized for high performance in numerous clinical specialties and procedures. Dartmouth Health includes Dartmouth Cancer Center, northern New England’s only National Cancer Institute-designated Comprehensive Cancer Centers and one of less than than 60 total nationally; Dartmouth Health Children’s, which includes the state’s only children’s hospital (Children’s Hospital at DHMC/CHaD) and more than 20 locations around the region; eight member hospitals in Lebanon, Keene, Claremont, Hampstead, and New London, NH, and Windsor and Bennington, VT; Dartmouth Health Home Care; Dartmouth Health Connected Care Center for Telehealth, serving patients as far away as Texas; and more than 30 primary and multi-specialty clinics across New Hampshire and Vermont. Through its partnership with Dartmouth College, Dartmouth’s Geisel School of Medicine and the White River Junction VA Medical Center, Dartmouth Health trains nearly 400 medical residents and fellows annually and performs cutting-edge research and clinical trials with international impact. Dartmouth Health and its more than 16,000 employees are committed to serving the healthcare needs of everyone in the communities it serves and to providing every patient with exceptional, state-of-the-art, personalized care. Learn more at dartmouth-health.org.